SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Pharmaceuticals, Inc. Release: RE-LY Sub-Analysis Suggests Pradaxa® (Dabigatran Etexilate Mesylate) Associated With Similar Bleeding Rates And Thromboembolic Complications In Surgery Versus Warfarin